FDA Public Meeting on Electronic Records and Signatures June 11, 2004 Presentation of the Industry Coalition on 21CFR Part 11 Alan Goldhammer, PhD Chair.

Slides:

Advertisements

Similar presentations

Drug Information for Consumers and Healthcare Professionals Food and Drug Law Institute Annual Meeting Alan Goldhammer, PhD Associate VP Regulatory Affairs.

Advertisements

Radiopharmaceutical Production

The New GMP Annex 11 and Chapter 4 Deadline for coming into operation: 30 June 2011.

Supporting National e-Health Roadmaps WHO-ITU-WB joint effort WSIS C7 e-Health Facilitation Meeting 13 th May 2010 Hani Eskandar ICT Applications, ITU.

21 CFR Part 11 Regulatory Overview and What’s New with the FDA

Public Key Infrastructure (PKI) Hosting Services.

New GAMP Good Practice Guide for Electronic Record and Signature Compliance Arthur D. Perez, Ph.D. Chairman, GAMP Americas.

Regulatory Compliant Performance Improvement for Pharmaceutical Plants AIChE New Jersey Section 01/13/2004 Murugan Govindasamy Pfizer Inc.

Integrating CMC Review & Inspection Industry Recommendations Joe Anisko April 24, 2003.

Coping with Electronic Records Setting Standards for Private Sector E-records Retention.

Electronic Government: Law, Policy, and Practice Jonathan P. Womer Information Policy and Technology Office of Management and Budget

Introduction to Regulation

1 Promoting Safe Medicine With Track and Trace Systems SRC Technologies, Inc.

SAI K. RAMASWAMY DR. GRETCHEN A. MOSHER NC-213,KANSAS CITY HARPC: Preventive Controls & Food Safety Implications 1 NC-213The U.S. Quality Grains Research.

21 CFR PART 11 REGULATIONS RECOMMENDATIONS FOR CHANGES FDA PUBLIC MEETING ON PART 11 REGULATIONS – JUNE 11, 2004 NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION.

Industry Coalition on 21 CFR Part 11 Recommendations for Achieving Compliance with the Electronic Records and Electronic Signatures Regulation.

CDRH Software Regulation

Session 6: Data Integrity and Inspection of e-Clinical Computerized Systems May 15, 2011 | Beijing, China Kim Nitahara Principal Consultant and CEO META.

11/2/991 CDER’s 21 CFR Part 11 Implementation Study Greg Brolund Associate Director, Office of Information Technology, CDER/FDA.

1. RCC Industry Panel – Consumer Products Presentation to RCC Stakeholder Dialogue Session June 20, 2013 Darren Praznik President & CEO, Canadian Cosmetic,

United States-Canada Regulatory Cooperation Council United States-Canada Regulatory Cooperation Council January 30, 2012 Washington D.C

21 CFR Part 11 A Food Industry Perspective FDA Public Meeting June 11, 2004 Sia Economides Center Director Center for Development of Research Policy and.

Executive summary prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9 QUALITY RISK MANAGEMENT.

MethodGXP The Solution for the Confusion.

Compliance and Regulation for Mobile Solutions Amanda J. Smith Messick & Lauer, P.C. May 16, 2013.

Evolving IT Framework Standards (Compliance and IT)

BITS Proprietary and Confidential © BITS Security and Technology Risks: Risk Mitigation Activities of US Financial Institutions John Carlson Senior.

Comments Presentation for Part11 FDA Public Meeting Docket # 2004N-0133 Venue and Date: 429 L'Enfant Plaza, SW Washington, DC June 11, 2004.

FDA Docket No. 2004N-0133 Themes for Renewal of 21 CFR Part 11 Rule & Guidance by Dr. Teri Stokes, GXP International

Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.

STORAGE MANAGEMENT/ EXECUTIVE: Managing a Compliant Infrastructure Processes and Procedures Mike Casey Principal Analyst Contoural Inc.

1 Secure Commonwealth Panel Health and Medical Subpanel Debbie Condrey - Chief Information Officer Virginia Department of Health December 16, 2013 Virginia.

State Alliance for e-Health Conference Meeting January 26, 2007.

© 2011 Underwriters Laboratories Inc. All rights reserved. This document may not be reproduced or distributed without authorization. ASSET Safety Management.

1 PAT and Biological Products Tom Layloff FDA-SGE Management Sciences for Health The views expressed here are those of the author and not necessarily.

PwC 21 CFR Part 11 – A Risk Management Perspective Patrick D. Roche 07 March 2003, Washington D.C.

FDA’s Perspective on the “Pharmaceutical cGMPs for the 21st Century” Initiative David J. Horowitz, Esq. Director, CDER/FDA, Office of Compliance Advisory.

FDA Part 11 Public Meeting Part 11 Simplification, and a Return to the Original Intent Presented By: Martin Browning, EduQuest, Inc.

+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.

Electronic Signatures in Global and National Commerce Act (E-SIGN) Office of Environmental Information USEPA January 10, 2001.

Part 11, Electronic Records; Electronic Signatures

The FDA Regulatory and Compliance Symposium Preparing for the FDA’s Risk-Based Inspections Presented By: Martin Browning, EduQuest, Inc.

PhRMA Perspective on FDA Final Report FDA Advisory Committee on Pharmaceutical Sciences October 20, 2004 G.P. Migliaccio, Pfizer Inc.

Strengthened Oversight of Imports under the Proposed Imported Food Sector Product Regulations.

Session 52-1 Session 52 E-Signature: Implications of the E-SIGN Legislation for Student Aid 1.

Part 11 Public Meeting PEERS Questions & Responses The opinions expressed here belong to PEERS members and not the corporate entities with which they are.

UPCOMING CHANGES TO IN-VITRO DIAGNOSTICS (IVDs) AND LABORATORY DEVELOPED TESTS (LDTs) REGULATIONS Moj Eram, PhD November 5, 2015.

Hajar Sabuur Johnson & Johnson Worldwide Information Security June 16, 2005

Progress in FDA’s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003.

FDA Part 11 Public Meeting Washington, DC June 11, 2004 Paul D’Eramo Executive Director Worldwide Policy & Compliance Management Quality & Compliance Services.

FDA job description  Regulates about 25% of all consumer purchases  Mission summary: protect and advance public health  Products: food, cosmetics, drugs,

FDA Public Meeting Electronic Records; Electronic Signatures Docket No. 2004N-0133 Madeleine Kennedy & Michael Rutherford Eli Lilly and Company 11 June.

6/11/04Part 11 Public Meeting1 Risk-Based Approach Scott M Revolinski Washington Safety Management Solutions Carolyn Apperson-Hansen Cleveland Clinic Foundation.

FDA Risk Communication Nancy M. Ostrove, PhD Senior Advisor for Risk Communication Risk Communication Advisory Committee February 28, 2008.

Examining Drug Quality Regulation Douglas C. Throckmorton, MD Deputy Director Center for Drug Evaluation and Research Public Meeting on 21 CFR February,

DATA MANAGEMENT AND IT IN BA/BE STUDIES DR. SHIVPRAKASH MANAGING DIRECTOR SYNCHRON RESEARCH SERVICES PVT. LTD., INDIA.

The CDRH Software Message (October 19, 2002) John F Murray Jr.. Center for Devices & Radiological Health US Food and Drug Administration

ValGenesis Closed Loop Change Management ValGenesis, Inc Christy Street, Fremont, CA Ph:

© 2011 Underwriters Laboratories Inc. Conformity Assessment Best Practices and Advancing GRP in EAC: The Value of Public-Private Partnerships EAC Workshop.

1 Developed by: U-MIC To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the.

The technology behind the USPS EPM. AND COMPLIANCE March 25, 2004 Adam Hoffman.

21 CFR PART 11.

FDA 21 CFR Part 11 Compliance

FDA's Two New Draft Guidance on Software and Device

Clinical Trials Validation, 21 CFR Part 11 Compliance

FDA Regulated Special Interest Group

Regulatory Perspective of the Use of EHRs in RCTs

Radiopharmaceutical Production

Presentation transcript:

FDA Public Meeting on Electronic Records and Signatures June 11, 2004 Presentation of the Industry Coalition on 21CFR Part 11 Alan Goldhammer, PhD Chair of the Coalition

Advanced Medical Technology Association America’s Blood Centers Animal Health Institute Biotechnology Industry Organization Consumer Healthcare Products Association Cosmetic, Toiletry, and Fragrance Association Council for Responsible Nutrition Council on Radionuclides and Radiopharmaceuticals Generic Pharmaceutical Association Medical Device Manufacturers Association National Electrical Manufacturers Association National Food Processors Association National Grain and Feed Association Pharmaceutical Research and Manufacturers of America

Coalition Background Formed in mid-2000 Goal: Provide a Broad Industry Perspective on the Regulation to FDA Actions: Provided Comments to FDA on a Variety of Issues including: –Scope –Validation –Time Stamps

Effect of the Regulation on Business Processes It is intended to enable electronic submission – without paper copies, and review of components of marketing applications,and related documents It is intended to facilitate industry and FDA use of more efficient and effective business processes: e- Records and e-Signatures replace many paper- based processes. It is intended to aid in avoiding mistakes and fraud, preserving and protecting electronic GxP records, and maintaining product quality and data integrity.

Effect of the Regulation (cont’d) Leads to harmonization of e-Records and e- Signatures within and across agencies and the regulated industries Has served as a general set of requirements to software vendors. Has advanced awareness of this issue

Problems with the Regulation Too Prescriptive in Terms of Technology Difficult to Interpret Uncertain Cost (> $2 billion estimated by the pharmaceutical industry)

Other Federal Approaches Government Paperwork Elimination Act (GPEA), Pub. L. No , §§ (1998) –OMB Guidance on GPEA, agency considerations of cost, risk, and benefit, as well as any measures taken to minimize risks, should be commensurate with the level of sensitivity of the transaction "Electronic Records and Signatures in Global and National Commerce Act" (E-SIGN) (Pub.L , § 1 (2000)

LEGAL CONSIDERATIONS IN DESIGNING AND IMPLEMENTING ELECTRONIC PROCESSES: A GUIDE FOR FEDERAL AGENCIES ercrime/eprocess.htm

Where Should We Head?? In accordance with the OMB Guidance on GPEA, agency considerations of cost, risk, and benefit, as well as any measures taken to minimize risks, should be commensurate with the level of sensitivity of the transaction. Low-risk information processes may need only minimal safeguards, while high-risk processes may need more. In the context of legal and litigation risks, "low-risk information processes" are those that have a small chance of generating significant liability, financial impact, or litigation that would have a significant effect on the agency.

Some Industries Already Have Moved in this Direction Foods – Hazard Analysis and Critical Control Point (HACCP ) Medical Devices – Quality Systems ("Each manufacturer shall establish and maintain a quality system that is appropriate for the specific device(s) designed or manufactured, and that meets the requirements of this part." ) Process Analytical Technology (PAT) – emerging standard for the pharmaceutical industry.

Risk/Benefit Driven Approach Apply control mechanisms for e-Records proportional to potential impact on public health. Use hierarchical approach to implementation for applications, data and reports, similar to SUPAC. Develop benefit-driven approach acceptable to FDA and regulated industries.

New Scope and Application More Realistic Risk Based Approach Withdrawal of Compliance Policy Guide Recognition of the Need to Search for Practical Solutions

Risk Based Approach in Part 11 Final Guidance Current Part 11 Final Guidance emphasizes role of risk assessment for some Part 11 controls –validation –audit trails –record retention

Risk Based Approach in Part 11 Final Guidance “We (FDA) recommend that you base your approach on a justified and documented risk assessment and a determination of the potential of the system to affect product quality and safety, and record integrity “ [Lines ]

What is a Risk Based Approach to Part 11 Don’t limit use of risk based approach. Organizations should be allowed to apply their risk based approach to any area of electronic records There are a multitude of risk-based approaches and tools FDA should not specify any particular approach or tools to be used. If a risk based approach is used then it should be defined and documented.

Key Issues with E-Records Record Security Authenticity Authority/Accountability

E-Record Regulatory Paradigm Build Upon Existing Predicate Regulations Use Hardware, Software, & Best Business Practices Reconsider the Need for the Current Part 11 Regulation from the practical and enforcement points of view and in light of the lessons learned to date.